Inhibrx Biosciences (INBX) Invested Capital (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Invested Capital data on file, last reported at $108.6 million in Q4 2025.

• Invested Capital for Q4 2025 came in at $108.6 million, down 18.74% year-over-year; the trailing twelve-month figure through Dec 2025 was $108.6 million (down 18.74% YoY), and the FY2025 annual result was $108.6 million, down 18.74% from the prior year.
• Invested Capital declined to $108.6 million in Q4 2025 per INBX's latest filing, from $136.7 million in the prior quarter.
• Over five years, Invested Capital peaked at $219.4 million in Q2 2024 and troughed at -$24.8 million in Q2 2023.
• A 3-year average of $118.0 million and a median of $133.6 million in 2024 frame the typical range for Invested Capital.
• On a YoY basis, Invested Capital climbed as much as 1569.23% in 2025 and fell as far as 23.49% in 2025.
• A 3-year view of Invested Capital shows it stood at $43.5 million in 2023, then jumped by 207.07% to $133.6 million in 2024, then retreated by 18.74% to $108.6 million in 2025.
• Business Quant data shows INBX's Invested Capital at $108.6 million in Q4 2025, $136.7 million in Q3 2025, and $167.8 million in Q2 2025.